Medical Affairs

Marinus Pharmaceuticals, Inc. is committed to forwarding science and research in rare seizure disorders, and having a positive impact on the lives of patients and caregivers. We strive to develop safe, effective, and innovative therapies, and provide support and education to the rare disease community.

Learn more about the ways that Marinus is shaping the future of treatments

Our Guiding Principles

At Marinus, integrity and trust are of the utmost importance. That is why we abide by BIO patient engagement principles as we work with patient advocacy organizations to better support the patients we serve, and to help raise awareness and understanding of the unmet needs we work to address. You can learn more about these principles here.

Our guiding principles

Compassionate Use Policy

We take our responsibility to act as a true partner with the medical community very seriously and are committed to ensuring our innovations reach as many patients as possible, as quickly as possible.

Request a copy of the company’s compassionate use policy


Marinus is planning to offer the following programs to further support patients affected by epilepsy and neuropsychiatric disorders.

Icon Beaker

Educational Grants

Dedication to improving the lives of patients and caregivers

Icon Brain 2

Expanded Access Program

Providing investigational drugs to qualified patients through expanded access programs

Icon Book

Support & Sponsorship

Supporting activities and programs focused on rare seizure disorders


Helpful Resources on Ganaxolone

Multi Ethnic Group Of Nursing Students In Class

Ganaxolone in Status Epilepticus

Kapur et al. 2019 Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus

Holtkamp et al. 2005 Predictors and Prognosis of Refractory Status Epilepticus
Treated in a Neurological Intensive Care Unit

Hocker et al. 2013 Predictors of Outcome in Refractory Status Epilepticus

Chamberlain et al. 2020 Efficacy of levetiracetam, fosphenytoin, and valproate for
established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial

Saporito et al. 2019 Intravenously Administered Ganaxolone Blocks DiazepamResistant Lithium-Pilocarpine–Induced Status Epilepticus in Rats: Comparison with Allopregnanolones

Background on CDKL5 Deficiency Disorder

Olson et al. 2019 Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review

Demarest et al. 2019 CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development

Background on Tuberous Sclerosis Complex

Di Michele et al. 2003 GABAA receptor active steroids are altered in epilepsy patients with tuberous sclerosis

Marinus Posters Presented During AES

Intravenous Ganaxolone Achieves Rapid and Does-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory with Refractory Status Epilepticus

Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus

Ganaxolone in CDKL5 Deficiency Disorder: Open-Label Phase 2a Results and Ongoing Pivotal Phase 3 Study Design

Long-term, Durable Seizure Frequency Reduction in Children with CDKL5 Deficiency Disorder (CDD) Treated with Ganaxolone

Population Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalographic Effects of Ganaxolone in Healthy Subjects